PART 01:Executive summary • Highlights PART 02:Scope of the report • Market overview • Top-vendor offerings PART 03:Market research methodology • Research methodology • Economic indicators PART 04:Introduction • Key market highlights PART 05:Pipeline portfolio • Ulcerative colitis • Crohn's disease • IBS PART 06:Market landscape • Global gastrointestinal therapeutics market PART 07:Market segmentation by disease type • Overview PART 08:Global IBD therapeutics market • Global ulcerative colitis drugs market • Global Crohn's disease drugs market • Market segmentation by molecule type PART 09:Global IBS therapeutics market PART 10:Global gastrointestinal OTC drugs market PART 11:Geographical segmentation • Global gastrointestinal therapeutics market by geography 2015-2020 • Gastrointestinal therapeutics market in Americas • Gastrointestinal therapeutics market in EMEA • Gastrointestinal therapeutics market in APAC PART 12:Market drivers • Increasing consumption of biologics • Tentative approval of late stage molecules • Development of novel therapies using innovative technologies • Improved diagnostic tools increasing the treatment-seeking population PART 13:Impact of drivers PART 14:Market challenges • Increased consumption of OTC medications • Unknown etiology of IBD and IBS • Discontinuation of drugs under development and from the market PART 15:Impact of drivers and challenges PART 16:Market trends • Patient assistance programs • Emergence of biosimilars • Rise in self-medication • Focus on regenerative medicines • Strategic alliances and M&A PART 17:Vendor landscape • Competitive scenario • Other prominent vendors PART 18:Key vendor analysis • AbbVie • Johnson & Johnson • Takeda • Allergan • UCB PART 19:Appendix • List of abbreviations PART 20:Explore Technavio List of Exhibits Exhibit 01:Product offerings Exhibit 02:Global gastrointestinal therapeutics market: Key buying criteria 2015 Exhibit 03:Global gastrointestinal therapeutics market: Key customer segments Exhibit 04:Global ulcerative colitis therapeutics market: Pipeline portfolio Exhibit 05:Global Crohn's disease therapeutics market: Pipeline portfolio Exhibit 06:Global IBS therapeutics market: Pipeline portfolio Exhibit 07:Global gastrointestinal therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 08:Global gastrointestinal therapeutics market: Factors affecting growth 2015 and 2020 Exhibit 09:Approval and patent expiries of top selling biologics Exhibit 10:Global gastrointestinal therapeutics market 2016-2020 ($ billions) Exhibit 11:Global gastrointestinal disorder therapeutics market segmentation: Growth cycle analysis Exhibit 12:Five forces analysis Exhibit 13:Global gastrointestinal therapeutics market by disease type: Revenue share 2015 Exhibit 14:Global gastrointestinal therapeutics market by disease type: Growth lifecycle analysis Exhibit 15:Global gastrointestinal therapeutics market by disease type 2015-2020 Exhibit 16:Global IBD therapeutics market by type: Revenue share 2015 Exhibit 17:Global IBD therapeutics market by type 2015-2020 Exhibit 18:Global IBD therapeutics market segmentation: Growth lifecycle analysis Exhibit 19:Global ulcerative colitis drugs market 2015-2020 ($ billions) Exhibit 20:Global Crohn's disease drugs market 2015-2020 ($ billions) Exhibit 21:Global IBD therapeutics market by molecule type 2015 Exhibit 22:Biologics in global IBD therapeutics market 2015-2020 ($ billions) Exhibit 23:Small molecules in global IBD therapeutics market 2015-2020 ($ billions) Exhibit 24:Global IBS therapeutics market 2015-2020 ($ billions) Exhibit 25:Drugs that underwent Rx-to-OTC switch in the US Exhibit 26:Global gastrointestinal OTC drugs market 2015-2020 ($ billions) Exhibit 27:Global gastrointestinal therapeutics market by geography 2015-2020 Exhibit 28:Global gastrointestinal therapeutics market by geography 2015 and 2020 Exhibit 29:Global gastrointestinal therapeutics market by geography 2015-2020 ($ billions) Exhibit 30:Global gastrointestinal therapeutics market by geography: Market share 2015 Exhibit 31:Global gastrointestinal therapeutics market by geography: Disease type 2015 Exhibit 32:Global gastrointestinal therapeutics market by geography: Market growth lifecycle analysis 2015 Exhibit 33:Global gastrointestinal therapeutics market by country: Revenue and growth rate analysis Exhibit 34:Opportunity analysis of gastrointestinal therapeutics market in Americas Exhibit 35:Gastrointestinal therapeutics market in Americas 2015-2020 ($ billions) Exhibit 36:Opportunity analysis of gastrointestinal therapeutics market in EMEA Exhibit 37:Gastrointestinal therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 38:Opportunity analysis of gastrointestinal therapeutics market in APAC Exhibit 39:Gastrointestinal therapeutics market in APAC 2015-2020 ($ billions) Exhibit 40:Impact of drivers and challenges on global gastrointestinal therapeutics market Exhibit 41:Biologics for IBD: market share 2012-2022 Exhibit 42:Few biologics under development for gastrointestinal disorders Exhibit 43:Impact of drivers Exhibit 44:Rx-to-OTC switch: Promoters and inhibitors Exhibit 45:Gastrointestinal therapeutics discontinued from development or market Exhibit 46:Impact of drivers and challenges Exhibit 47:Global gastrointestinal therapeutics market: Impact assessment of key trends Exhibit 48:Gastrointestinal therapeutics with patient assistance programs in US Exhibit 49:Biosimilars under development for gastrointestinal disorders Exhibit 50:Regenerative medicines for IBD under development Exhibit 51:Key vendors ranking 2015 Exhibit 52:Key vendors: Geographical presence Exhibit 53:Market vendors: Competitive scenario 2015-2020 Exhibit 54:AbbVie: Profile Exhibit 55:AbbVie: Strength analysis Exhibit 56:AbbVie: Growth strategy matrix Exhibit 57:AbbVie: Opportunity assessment Exhibit 58:AbbVie: YoY growth and revenue of HUMIRA 2012-2014 ($ billions) Exhibit 59:Johnson & Johnson: Profile Exhibit 60:Johnson & Johnson: Strength analysis Exhibit 61:Johnson & Johnson: Growth strategy matrix Exhibit 62:Johnson & Johnson: Opportunity assessment Exhibit 63:Johnson & Johnson: YoY revenue and growth rate of Remicade 2013-2015 ($ billions) Exhibit 64:Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2013-2015 ($ billions) Exhibit 65:Takeda: Profile Exhibit 66:Takeda: Strength analysis Exhibit 67:Takeda: Growth strategy matrix Exhibit 68:Takeda: Opportunity assessment Exhibit 69:Allergan: Profile Exhibit 70:Allergan: Strength analysis Exhibit 71:Allergan: Growth strategy matrix Exhibit 72:Allergan: Opportunity assessment Exhibit 73:Allergan: Revenue of gastrointestinal therapeutics 2015 ($ millions) Exhibit 74:UCB: Profile Exhibit 75:UCB: Strength analysis Exhibit 76:UCB: Growth strategy matrix Exhibit 77:UCB: Opportunity assessment

AbbVie, Johnson & Johnson, Takeda, Allergan, UCB, 4SC, Ajinomoto Pharmaceuticals, Alfa Wassermann, Alizyme, Amgen, Anterogen, Ardelyx, Arena Pharmaceuticals, Astellas, AstraZeneca, Astellas Pharma, Avaxia Biologics, Biogen Idec, BioLineRx, Celgene, ChemoCentryx, Cosmo Pharmaceuticals, Drais Pharmaceuticals, Eisai, Eli Lilly, Enlivex Therapeutics, F. Hoffmann-La Roche, Ferring Pharmaceuticals, FF Pharma, Galapagos, Gilead Sciences, GlaxoSmithKline, Hutchison Medi Pharma, Immune Pharmaceuticals, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Kaken Pharmaceutical, Kang Stem Biotech, Kissei Pharmaceutical, Kyowa Hakko Kirin, Lexicon Pharmaceuticals, Lipid Therapeutics, Meda, Merck, Mesoblast, Mitsubishi Tanabe, Mochida Pharmaceutical, Morphotek, Neovacs, Nestle, Norgine, Novartis, Ono Pharmaceutical, Pfizer, Procter & Gamble, Qu Biologics, Receptos, RedHill Biopharma, Salix Pharmaceuticals, Shield Therapeutics, Sterna Biologicals, Synergy Pharmaceuticals, Synthetic Biologics, TiGenix, Tillotts Pharma, TopiVert, TSD Japan, Zeria Pharmaceutical.